Cardio Diagnostics director awarded stock options

Cardio Diagnostics Holdings director Burton Paul Frederick received a grant of stock options, providing additional equity-based compensation.

Rhea-AI Filing Summary

Cardio Diagnostics Holdings director Burton Paul Frederick received a grant of stock options, providing additional equity-based compensation. The award covers 2,854 options to buy Common Stock at an exercise price of $2.19 per share, expiring on June 30, 2036. Following this grant, Frederick holds 13,318 stock options directly.

Insider Trade Summary

Grant/Award: 2,854 shares

Grant/Award 1 txn

Insider Burton Paul Frederick

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy)	2,854	$2.19	$6K

Holdings After Transaction: Stock Options (Right to Buy) — 13,318 contracts (Direct)

Key Figures

Options granted: 2,854 options Exercise price: $2.19 per share Expiration date: June 30, 2036 +2 more

5 metrics

Options granted 2,854 options Stock options granted on June 30, 2026

Exercise price $2.19 per share Conversion or exercise price for granted options

Expiration date June 30, 2036 Expiration of granted stock options

Underlying shares 2,854 shares Common Stock underlying newly granted options

Total options after grant 13,318 options Direct derivative holdings following transaction

Key Terms

Stock Options (Right to Buy), Common Stock, Grant, award, or other acquisition

3 terms

Stock Options (Right to Buy) financial

"security_title: "Stock Options (Right to Buy)""

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cardio Diagnostics (CDIO) report for Burton Paul Frederick?

Cardio Diagnostics reported that director Burton Paul Frederick received a grant of 2,854 stock options. These derivative securities give him the right to buy Common Stock at $2.19 per share and are part of his equity-based compensation package.

What is the exercise price of the new Cardio Diagnostics (CDIO) stock options?

The newly granted stock options to Burton Paul Frederick have an exercise price of $2.19 per share. This price is the fixed cost at which he can purchase Cardio Diagnostics Common Stock before the options expire on June 30, 2036.

How many Cardio Diagnostics (CDIO) options does Burton Paul Frederick hold after this grant?

After this stock option grant, Burton Paul Frederick holds 13,318 stock options. This total reflects his direct derivative holdings in Cardio Diagnostics, including the 2,854 options granted on June 30, 2026 as compensation.

When do Burton Paul Frederick’s new Cardio Diagnostics (CDIO) options expire?

The 2,854 stock options granted to Burton Paul Frederick expire on June 30, 2036. He may choose to exercise them at $2.19 per share any time before that expiration date, subject to applicable plan and agreement terms.

Are Burton Paul Frederick’s new Cardio Diagnostics (CDIO) options direct or indirect holdings?

The Form 4 shows Burton Paul Frederick’s new stock options as direct holdings. The ownership code is listed as “D,” indicating he personally holds the derivative securities rather than through an intermediary entity or trust.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 12:20 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burton Paul Frederick

(Last) (First) (Middle)

311 W. SUPERIOR ST., SUITE 444

C/O CARDIO DIAGNOSTICS HOLDINGS, INC.

(Street)

CHICAGO ILLINOIS 60654

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cardio Diagnostics Holdings, Inc. [ CDIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$2.19	06/30/2026		A		2,854		06/30/2026	06/30/2036	Common Stock	2,854	$2.19	13,318	D

Explanation of Responses:

	/s/Elisa Luqman as attorney-in-fact for Paul Burton	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)